

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/CA05/000593

International filing date: 18 April 2005 (18.04.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/521,394  
Filing date: 16 April 2004 (16.04.2004)

Date of receipt at the International Bureau: 17 August 2005 (17.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

# PATENT COOPERATION TREATY

From the RECEIVING OFFICE

<p>To:</p> <p style="text-align: center;">The International Bureau of WIPO 34, chemin des Colombettes 1211, Geneva 20 Switzerland</p>	<h2 style="margin: 0;">PCT</h2> <p style="margin: 10px 0;">NOTIFICATION OF DATE OF RECEIPT OF PRIORITY DOCUMENT OR OF PRIORITY APPLICATION NUMBER</p> <p style="margin: 10px 0;">(PCT Administrative Instructions, Section 323(a), (b) and (c))</p>						
<p>Applicant's or agent's file reference <b>55326.2</b></p>	<p>Date of mailing <span style="float: right;">12 August 2005 (12-08-2005)</span> <i>(day/month/year)</i></p>						
<p>International application No. <b>PCT/CA2005/000593</b></p>	<p>International filing date <span style="float: right;">18 April 2005 (18-04-2005)</span> <i>(day/month/year)</i></p>						
<p>Applicant <b>THE GOVENORS OF THE UNIVERSITY OF ALBERTA ET AL</b></p>							
<p>1. <input checked="" type="checkbox"/> This receiving Office hereby gives notice of the receipt of the priority document(s) identified below on:</p> <p style="text-align: center;"><u>04 August 2005 (04.08.2005)</u></p> <p>2. <input type="checkbox"/> This receiving Office hereby gives notice of the receipt of a request (made under Rule 17.1(b)) to prepare and transmit to the International Bureau the priority document(s) identified below on:</p>  <p><b>Identification of the priority document(s):</b></p> <table style="width: 100%; border: none;"> <thead> <tr> <th style="text-align: left; width: 33%;">Priority date</th> <th style="text-align: left; width: 33%;">Priority application No.</th> <th style="text-align: left; width: 33%;">Country or regional Office or PCT receiving Office</th> </tr> </thead> <tbody> <tr> <td>16 April 2004 (16-04-2004)</td> <td>60/ 521,394</td> <td>US</td> </tr> </tbody> </table>		Priority date	Priority application No.	Country or regional Office or PCT receiving Office	16 April 2004 (16-04-2004)	60/ 521,394	US
Priority date	Priority application No.	Country or regional Office or PCT receiving Office					
16 April 2004 (16-04-2004)	60/ 521,394	US					
<p>Name and mailing address of the Receiving Office/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001(819)953-2476</p>	<p>Authorized Officer</p> <p style="text-align: center;">Terence Teoh (819) 997-6295</p>						

PA 1343804

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


July 15, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/521,394

FILING DATE: April 16, 2004

By Authority of the  
Under Secretary of Commerce for Intellectual Property  
and Director of the United States Patent and Trademark Office



*M. Tarver*

M. TARVER  
Certifying Officer

# TRANSMITTAL

Electronic Version v1.1

Stylesheet Version v1.1.0

<b>Title of Invention</b>	<b>ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE</b>	
Application Number :		
Date :		
First Named Applicant:	Hoon SUNWOO	
Confirmation Number:		
Attorney Docket Number:	10230.48	
<p>I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.</p> <p>I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.</p>		
Submitted By:		Elec. Sign.
Edward Yoo Registered Number: 41435		Sign. Capacity Agent

Documents being submitted:	Files
us-declaration	10230.48-usdecl.xml us-declaration.dtd us-declaration.xsl
us-fee-sheet	10230.48-usfees.xml us-fee-sheet.xsl us-fee-sheet.dtd
us-request	10230.48-usrequ.xml us-request.dtd us-request.xsl
application-body	ProvAppAsFiled-trans.xml us-application-body.xsl application-body.dtd wipo.ent mathml2.dtd mathml2-qname-1.mod isoamsa.ent isoamsb.ent isoamsc.ent isoamsn.ent isoamso.ent isoamsr.ent isogr3.ent isomfrk.ent isomopf.ent isomscr.ent isotech.ent isobox.ent isocyr1.ent isocyr2.ent isodia.ent isolat1.ent isolat2.ent isonum.ent isopub.ent mmlextra.ent mmlalias.ent soextblx.dtd tbl1.tif tbl2.tif tbl3.tif tbl4.tif tbl5.tif fig1.tif fig2.tif
Comments	

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Electronic Version v11

Stylesheet Version v10

**Title of  
Invention**

**ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT  
OF CELIAC DISEASE**

As the below named inventors, we declare that:

This declaration is directed to the invention titled: " ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE"

We believe that we are the original and first inventors of the subject matter which is claimed and for which a patent is sought;

We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

**FULL NAME OF INVENTORS:**

Inventor 1: Hoon SUNWOO	Agent
Signature :	Citizen of : CA
Inventor 2: Jeong S. SIM	Agent
Signature :	Citizen of : CA

# APPLICATION DATA SHEET

Electronic Version v14

Stylesheet Version v14.0

## Title of Invention

ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE

Application Type : provisional, utility

Attorney Docket Number : 10230.48

Correspondence address:

Customer Number: 22828



## Inventors Information:

### Inventor 1:

**Applicant Authority Type:** Inventor  
**Citizenship:** CA  
**Given Name:** Hoon  
**Family Name:** SUNWOO  
**Residence:**  
**City of Residence:** Edmonton  
**Country of Residence:** CA  
**Address-1 of Mailing Address:** c/o University of Alberta  
**Address-2 of Mailing Address:** 8625 - 112 Street  
**City of Mailing Address:** Edmonton, Alberta  
**State of Mailing Address:**  
**Postal Code of Mailing Address:** T6G 2E1  
**Country of Mailing Address:** CA  
**Phone:**  
**Fax:**  
**E-mail:**

### Inventor 2:

**Applicant Authority Type:** Inventor  
**Citizenship:** CA  
**Given Name:** Jeong S.  
**Family Name:** SIM  
**Residence:**  
**City of Residence:** Edmonton

<b>Country of Residence:</b>	CA
<b>Address-1 of Mailing Address:</b>	c/o University of Alberta
<b>Address-2 of Mailing Address:</b>	8625 - 112 Street
<b>City of Mailing Address:</b>	Edmonton, Alberta
<b>State of Mailing Address:</b>	
<b>Postal Code of Mailing Address:</b>	T6G 2E1
<b>Country of Mailing Address:</b>	CA
<b>Phone:</b>	
<b>Fax:</b>	
<b>E-mail:</b>	



## Description

# ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE

### BACKGROUND OF INVENTION

[0001] The present invention generally relates to pharmaceutical or nutraceutical compositions comprising anti-gluten antibodies and methods for producing and using such antibodies. The compositions may comprise whole egg yolk, or processed egg yolk, or isolated or purified fractions of the egg yolk, and may be used in the active or prophylactic treatment of celiac disease.

[0002] Celiac disease (also known as celiac sprue, non-tropical sprue or gluten-sensitive enteropathy) is a common autoimmune condition triggered by ingesting wheat proteins called gluten. In cereal grains and flour, such as wheat, rye or barley, gluten is a complex mixture of proteins including alcohol-soluble monomers called gliadins and alcohol-insoluble polymers called glutenins. Gliadins can be

divided into alpha, gamma and omega types on the basis of their amino acid sequences and mobility on electrophoresis. The glutenin subunits can be divided into high molecular weight (HMG) and low molecular weight (LMG) groups.

[0003] The clinical spectrum of gluten sensitivity includes typical celiac disease associated with the classical features of fatigue, chronic diarrhoea, malabsorption of nutrients, weight loss, abdominal distension, anaemia, as well as a failure to thrive in young children.

[0004] The typical form of celiac disease has an incidence of approximately 1 in 2500 in people of European descent, and also occurs in North African and Asian populations in lower incidence. The atypical form is also found in those who have latent onset of the disease. In total, the incidence of typical and atypical forms is about 1 in 1500. Asymptomatic celiacs are discovered when relatives of celiacs are tested. Latent celiacs are defined as those who have one of the companion diseases such as other autoimmune disorders such as diabetes, arthritis, Sjogren's syndrome, thyroid disease, collagen vascular disease, and liver disease. When combined, these various presentations of celiac disease reach as high as 1 in 300.

[0005] In celiac patients, gluten triggers an auto-immune attack. The ingested gluten carries epitopes capable of activating T cells, so the process can be considered to be an autoimmune disease.

[0006] There are two major components leading to the disease: a genetic background and environmental factors that will trigger the disease to a full expression of typical or atypical symptoms.

[0007] The large majority of celiac patients express human leukocyte antigen HLA-DQ2 or DQ8 molecules, or both. Enterocytes, cells on the lining of the small intestine, have receptors which are 'programmed' by the Class II antigens to recognize gluten. The gluten binds to HLA receptors that are present on the enterocytes. When this binding occurs, there is a migration to the other side of the cells. This receptor-gluten complex can reach cells in the bloodstream. There are lymphocytes that are responsible for the production of toxic compounds that are ultimately responsible for tissue damage in the intestine. Among them, T helper I cells and cytokines apparently play a major role in a local inflammatory process and also stimulate B-cells differentiation in plasma cells producing antibodies.

[0008] Currently, the only acceptable treatment for celiac disease is strict adherence to a 100% gluten-free diet for life. An adherence to a gluten-free diet can prevent almost all complications caused by the disease. A gluten-free diet means avoiding all products that contain wheat, rye and barley, or any of their derivatives, for example in commercial soups, sauces, ice creams, hot dogs, and other foods.

[0009] However, this is a difficult task as there are many hidden sources of gluten found in the ingredients of many processed foods. Many commercial products, ready meals and convenience foods are made with wheat flour, gluten-containing wheat proteins or gluten-containing starches added as a filler, stabilizing agent or processing aid. These include sausages, fish fingers, cheese spreads, soups sauces, mixed seasonings, mincemeat for mince pies, and some medications and vitamin supplements. Another possible source of contamination of gluten-free products occurs when they are produced using the same production lines and equipment employed for making gluten-containing foods.

[0010] In view of the serious and widespread nature of celiac disease, there is a need for natural methods of treating or

ameliorating the effects of the disease are needed. The present invention is directed to addressing such a need.

#### **SUMMARY OF INVENTION**

- [0011] The present invention is directed at pharmaceutical or nutraceutical compositions for treating or preventing celiac disease comprising naturally occurring egg yolk components. In one embodiment, the compositions of the present invention comprise at least one egg yolk antibody to gluten proteins and essential nutrients in egg yolk for treatment of patients with celiac disease.
- [0012] The antibody used in the compositions may include polyclonal antibodies which have a masking activity against gluten proteins such as gliadin, high molecular glutenin, (HMG) and low molecular glutenin (LMG) found in wheat flour, and which act as a modulator of permeability in intestinal epithelium in those suffering from celiac disease.
- [0013] The antibodies are produced by immunizing fowl with gluten proteins and harvesting their eggs. Gluten proteins for immunization are produced by isolating the gliadin, HMG and LMG from wheat flour. The gliadin fraction is isolated from wheat flour by defatting the flour, removing starch, and then extracting gliadin fraction with alcohol. The glutenin fractions are isolated from wheat flour by

defatting flour, removing starch, and then extracting glutenin fractions with a reducing agent.

- [0014] The antibody preparations may comprise a single polyclonal antibody directed at one of gliadin, HMG or LMG. Alternatively, the antibody composition may comprise a cocktail of two or more polyclonal antibodies directed at combinations of gliadin, HMG or LMG.
- [0015] In one embodiment, the single polyclonal antibody may be a chicken anti-gliadin polyclonal antibody, which is prepared by immunizing a chicken with gliadin fractions, followed by collecting eggs from the immunized chicken, and separating egg yolk from the egg white.
- [0016] In another embodiment, the cocktail polyclonal antibodies are chicken anti-gliadin, HMG and LMG polyclonal antibodies by immunizing a chicken with three fractions, followed by collecting eggs from the immunized chicken, and separating egg yolk from the egg white.
- [0017] In the present invention, the compositions for treating patients with celiac disease may include formulations of egg yolk containing specific antibodies for oral administration. In particular, in addition to pharmaceutical and nutraceutical compositions, the egg yolk containing specific antibodies may be used as an ingredient in foods such as

bread, dairy products, margarine, mayonnaise, dressings, sauces, or any other food product which may include eggs or egg yolks as an ingredient.

[0018] The compositions may comprise dosage forms for oral administration include a formulation in which the antibodies are contained within an enteric coating that allows delivery of the active agent to the intestine. The formulations containing specific antibodies may be encapsulated in a dried form or in a liquid form, designed to resist digestion in acidic stomach conditions and to be delivered to affected areas of the intestine. The preferred effective amount of the antibody used in the preparations is about 30 mg daily, most favourably about 10 mg per meal prior to ingestion. The preparation can be used to treat patients with celiac disease by oral administration daily.

[0019]

#### **BRIEF DESCRIPTION OF DRAWINGS**

[0020] The invention will now be described by way of exemplary embodiments with reference to the accompanying drawings. In the drawings:

[0021] FIG. 1 is a block diagram showing a process of producing antibodies against gluten proteins and preparing antibody-

ies for the treatment of celiac disease, according to the present invention.

[0022] FIG 2 is a line graph showing a titer of antibodies from egg yolk of hyperimmunized laying hens during the immunization period.

#### DETAILED DESCRIPTION

[0023] The present invention provides for pharmaceutical or nutraceutical compositions for treating patients with celiac disease, or ameliorating their symptoms. When describing the present invention, all terms not defined herein have their common art-recognized meanings.

[0024] The term "antibody" includes polyclonal and monoclonal antibodies. Avian yolk antibodies have been reported to exhibit useful properties for both research and clinical applications as mammalian antibodies do (see, for example, U.S. Pat. Nos. 5,340,923; 5,585,098; 5,601,823; and 5,976,519). Egg yolks derived from a laying hen is inexpensive and more convenient and safer to handle as compared to the hyperimmunized mammalian sera. More importantly, yolk antibodies are able to stand up to the scrutiny under modern animal protection regulations (A. Polson et al., Immunol. Commun. 9:475 (1980); and B. Gottstein et al.). These facts suggest a potential use of



egg yolk as a commercial source of antibodies. Immunoglobulin Y (IgY) is an avian immunoglobulin.

[0025] The treatment of celiac disease is mediated by blocking glutens contained in foodstuffs before they are transported across the epithelial layer in intestines. With typical celiac disease, intact gluten is permeated into mucosal membrane without digestion. By binding to gluten with anti-gluten antibodies, gluten is passed through the intestines, rather than being transported into the mucosal membrane, thereby preventing the disease-causing toxicity.

[0026] A method of producing anti-gluten (gliadin, HMG and LMG) antibodies is shown schematically in Figure 1. The process comprises the steps of preparing antigenic materials from wheat flour, injecting the antigenic materials into egg-laying fowl, which may include ducks or hens, and selecting the eggs containing a high titer of egg yolk antibodies. Preferably, the eggs are further processed by separating the egg yolks from egg white and purifying egg yolk antibodies. The egg yolk containing antibody may be used as a food ingredient in the same manner as conventional egg yolks. For example, the egg yolk (or whole eggs) may be mixed with gluten free flour or nor-

mal wheat flour for making bread or be mixed with foods such as ice cream, coffee cream, mayonnaise, margarine, and salad dressing which use egg yolk as an emulsifier. Furthermore, the egg yolk, or purified or partially purified fractions of the egg yolk, may be formed into pharmaceutical or nutraceutical formulations for treating patients with celiac disease.

[0027] Gluten proteins may be prepared from wheat flour as described by Verbruggen et al. (Journal of Cereal Science, 1998, 28:25-32). Gliadin, HMG or LMG may each be isolated from wheat flour to be used as an antigenic material. It is preferable to enhance the immunogenicity of the gluten proteins by employing well-known adjuvants such as Freund's incomplete adjuvant or a flax oil, or other oil/water emulsions. The specific formulation of the antigenic material is not an essential element of the present invention.

[0028] The antigenic preparations are injected into laying fowl, such as hens, preferably at various intervals, to induce an immune response. The hens may be injected intramuscularly or sub-cutaneously. The specific mode of injection is not an essential element of the present invention. It is well known that the IgY antibodies produced by

the hens in response to such an immunochallenge are transferred and concentrated in the egg yolk.

[0029] Once the eggs are harvested, the eggs may be further processed to isolate the egg yolk, which itself may be further processed. The liquid egg yolk may be encapsulated or otherwise used in oral dosage forms. The egg yolk may be dried by spray or refractant drying method, and the resulting dried powder may be encapsulated or otherwise used in oral dosage forms.

[0030] Alternatively, a procedure of partial purification may be carried out to remove the majority of the non-aqueous bio-molecules and granules and preferably the majority of other proteins in the egg yolk. Any conventional method effective to achieve such a purpose is useful in the present invention, exemplary of which includes the use of PEG, dextran sulfate or a natural gum, such as sodium alginate, carrageenan and xanthan gum, to coprecipitate the undesired substances, and the use of an aqueous buffer or water to obtain an aqueous phase rich with antibodies.

[0031] In a preferred embodiment of the present invention, the yolk is firstly separated from the egg white, and then washed with distilled water to remove as much albumen as possible. The vitelline membrane encasting the yolk is

punctured, and the separated yolk fraction is then diluted with an effective amount of an aqueous buffer or water to form a suspension of the egg yolk. Preferably, the collected egg yolk is diluted with an aqueous buffer solution or distilled water in a ratio of about 1:2 to about 1:40 v/v, and more preferably, in a ratio of about 1:5 to about 1:30 v/v. pH value is reported to be a critical factor during the stage of partial purification (E. M. Akita and S. Nakai, J. Food Sci. 57:629 (1993)). For the best recovery of yolk antibodies, pH is preferably set within a range of about 5–7. Desirably, the temperature in this step is within a range of about 0.–60.d. The suspension of the egg yolk is gently agitated to form a homogenous mixture, and then allowed to stand for a period of time sufficient to form the aqueous and non-aqueous phases. The water insoluble materials, including non-aqueous bio-molecules such as lipoproteins, phospholipids, sterols and the like, are then removed from the aqueous yolk suspension by centrifugation. The resulting antibody-containing supernatant may then be separated from the viscous precipitant by decanting, suctioning, or other like methods known in the art.

[0032] Optionally but preferably, the yolk supernatant is further

treated with a high concentration of a non-denaturing salt to induce precipitation of the antibodies. Examples of the salts useful for precipitation of the yolk antibodies include but is not limited to  $\text{NaCl}$ ,  $\text{Na}_2\text{SO}_4$ ,  $(\text{NH}_4)_2\text{SO}_4$ ,  $\text{KCl}$ ,  $\text{CaCl}_2$  and  $\text{MgSO}_4$ . Preferred are  $\text{Na}_2\text{SO}_4$  and  $(\text{NH}_4)_2\text{SO}_4$ . The salt concentration for precipitating antibodies is important and, depending on the type of the salt, is usually present in an amount of higher than 15% and lower than 35% by weight, preferably in a range between 20% and 30% by weight of the salt, on the basis of the final volume of the yolk supernatant.

[0033] Alternatively, the antibodies may be purified or isolated using any conventional technique such as by immunoaffinity purification.

[0034] *EXAMPLES*

[0035] The following examples are intended solely to illustrate embodiments of the invention and are not intended to limit the scope of the claimed invention.

[0036] A first group of laying hens was injected with the gliadin at a concentration of 1.25 mg in a mixture of saline solution (0.5 ml per hen) and Freund's incomplete adjuvant or a flax oil (0.5 ml per hen). A second group of laying hens was injected with the HMG at a concentration of 1.25 mg

in a mixture of saline solution (0.5 ml per hen) and Freund's incomplete adjuvant or a flax oil (0.5 ml per hen). A third group of laying hens was injected with the HMG at a concentration of 1.25 mg in a mixture of saline solution (0.5 ml per hen) and Freund's incomplete adjuvant or a flax oil (0.5 ml per hen). A fourth group of laying hens was injected with the cocktail of gluten proteins containing gliadin (0.42 mg), HMG (0.42 mg) and LMG (0.42 mg) at a concentration of 1.26 mg in a mixture of saline solution (0.5 ml per hen) and Freund's incomplete adjuvant or a flax oil (0.5 ml per hen).

[0037] In each case, the antigenic materials are injected into subcutaneous skin sites on the neck of laying hens. After two weeks, each group of laying hens are injected again with the same formulations as above to boost the immunity of laying hens.

[0038] Specific activities of IgY in the egg yolk from laying hen-hyperimmunized with gluten proteins were monitored by an indirect ELISA during the immunization period as shown in FIG 2. The specific gliadin, HMG and LMG IgY activities are detected on day 0, rapidly increase from week 2 to week 4 and thereafter remain relatively high, showing no considerable decline up to 9 weeks. The spe-

cific anti-cocktail of gluten protein IgY activity also shows the similar pattern. As a result, a significant amount of IgY specific against gluten proteins are obtained from egg yolks from laying hens which are fed with wheat grains in feed formulation without immunization. However, 4- to 8 fold of specific antibodies are obtained from hyperimmunized laying hens after 4 weeks of initial immunization.

[0039] As shown in Figure 2, eggs containing high levels of specific IgY against gluten proteins are collected during the immunization period of 5 to 8 weeks and were then pooled to determine the amount of antibodies by ELISA. Egg yolks containing non-specific IgY were also prepared as a control. The concentrations of total and specific IgY in the collected egg yolks are assessed by ELISA and shown in TABLE 1.

TABLE 1 The concentrations of total IgY and specific IgY in egg yolk prepared from the hyperimmunized laying hens to gluten proteins.

	Concentration (mg/ml)		
	Total IgY	Specific IgY	Percentage (%)
Gliadin	12.5	0.88	7.0
HMG	12.1	0.79	6.5
LMG	11.3	0.81	7.2
Cocktail	12.9	1.05	8.1
Control	10.5	0.11	1.05

[0040] Thermal Stability

[0041] Whole egg yolk or purified IgY (containing 240  $\mu$ g IgY) was thermally treated at various temperatures (4, 20, 37, 62 and 85° C) for 30 min (TABLE 2). The antibody content in egg yolk IgY decreases with increasing temperature. The residual IgY content in PBS is sharply decreased by 8%, when the IgY samples are thermally treated at 85° C and the treatment lasted for 30 min. However the residual IgY was quite stable when thermally treated at temperature below 62°C. The components other than IgY in the egg yolk appeared to be significantly effective in protecting the IgY from thermal denaturation at 62°C. Therefore, IgY products should not be thermally exposed beyond 75°C. It is safe temperature region of commercial practice for egg pasteurization.

TABLE 2 The stability of egg yolk IgY (equivalent to 240 $\mu$ g IgY) after incubating at various thermal treatments for 30 min.

Temperature (C)	Whole Egg Yolk IgY Content ( $\mu$ g)	Purified IgY Content ( $\mu$ g)
4	239.9	239.9
20	238.9	238.9
37	237.6	235.7
62	233.1	234.7
85	19.7	15.9

[0042] Acid stability



[0043] Whole egg yolk or purified IgY (containing 240  $\mu$ g IgY) was treated at various acidic conditions (pH 2 to 7 in PBS) at 37°C for 2 hours (TABLE 3). After incubation, the solution was neutralized by 100 fold dilutions with PBS containing 0.05% Tween 20. Residual IgY content after various acidic treatments were concentrated by ELISA. The antibody content in whole egg yolk and purified IgY decreased with higher acidic conditions. The residual IgY content in PBS was decreased by more than 70%, when the IgY samples were treated at pH 2. However at higher than pH 3, IgY was relatively stable. The antibody content in egg yolk decreases with higher acidic conditions. The residual IgY content in the whole egg yolk decreases by more than 70%, when the whole egg yolk is treated at pH 2. However the residual IgY in the egg yolk is stable at over pH 3. Therefore, it appears to be important that IgY should not be subjected to acidic conditions at a pH less than 3 in food processing or storage.

TABLE 3 The stability of egg yolk IgY (equivalent to 240 $\mu$ g IgY) after incubating at various acidic conditions at 37C for 2 h.

pH conditions	Whole Egg Yolk IgY Content ( $\mu$ g)	Purified IgY Content ( $\mu$ g)
2	108.2	88.8
3	208.3	192.1
4	230.1	223.8
5	239.8	228.4
6	235.7	236.9
7	233.1	238.8

[0044] Protease stability

[0045] Whole egg yolk or purified IgY (containing 240  $\mu$ g IgY) was diluted with 50 mM Tris buffer (pH 7.0) and then homogenized at 1,500 rpm for 3 min (TABLE 4). Trypsin (Sigma) was dissolved at a concentration of 1 mg/mL of the Tris buffer and the IgY solution was mixed with the enzyme solution (1:9), and the mixtures were incubated at 37°C for time periods from 0 to 4 hours. A 0.5 mL sample of the incubation mixture was mixed with 0.05 mL of phenylmethyl sulfonyl fluoride solution (10 mM in isopropanol) to inactivate the enzyme. The remaining antibody activity was measured by ELISA. There is some degree of hydrolysis of IgY but significant portion of IgY activity is survived during harsh 4 hour digestion period.

This may be worthy noting that antibodies in egg yolk are more resistant to enzymatic breakdown in comparison with IgY in a pure form. It is likely that the extra egg yolk proteins and lipids play a protecting role against enzymatic attack. It is evident that IgY is vulnerable toward enzymatic hydrolysis during relatively extended duration. However, a significant portion of IgY survives a 4 hour digestion time period. This time factor is important to use IgY in food processing and oral application.

TABLE 4 The stability of egg yolk IgY (equivalent to 240 $\mu$ g IgY) after incubating with trypsin at 37C for 1-4 h.

Incubation time (h)	Whole Egg Yolk IgY Content ( $\mu$ g)	Purified IgY Content ( $\mu$ g)
0	240	240
1	199.3	178.9
2	177.2	131.8
4	152.9	102.7

#### [0046] In Vivo Stability

[0047] As IgY is a protein, it is possible that a significant amount of IgY given orally will be degraded and inactivated in the stomach and small intestine. However, the other components of egg yolk may have some protective effect. We have attempted to examine the remaining total IgY content in stomach and small intestine after feeding whole

egg yolk powder for various times (30 min, 1 h, 2 h, 4 h, 24 h and control groups) by using mice as an animal model. The result of residual IgY after feeding egg yolk powder to mice is shown in TABLE 5.

[0048] Twenty four albino mice (four mice per group) were fasted overnight before feeding. Dried egg yolk powder was continuously fed to mice ad libitum with free access to water. After 1/2, 1, 2, 4 and 24 hour, mice were terminated and dissected stomach and small intestine. The tissues were homogenized with buffer solution to neutralize the pH and enzyme activity with enzyme inhibitors and then centrifuged to collect supernatant including antibodies. The antibodies were concentrated by salt precipitation. The antibody activity was expressed by milligram of egg yolk antibody per gram of tissue. The control mice were also terminated before feeding as a control.

[0049] Yolk powder contains about 18mg of IgY per gram of egg yolk powder. After dissecting tissues from mice, the stomach and small intestine after removing digesta were measured. The wet weight of stomach is approximately 0.07–0.11g. The wet weight of small intestine is approximately 0.50–0.58g. Large intestine 0.22–0.28g. The weight of egg yolk powder in stomach is approximately

ranged from 0.3 –0.6 g. The weight of digesta in SI, 0.18–0.44g.

[0050] If IgY were not digested, total IgY content is approximately 90 mg/ gram of stomach tissue and total IgY content is approximately 9mg per gram of SI tissue.

**TABLE 5.** The concentrations of total IgY and specific IgY of yolks after feeding egg yolk powder to mouse.

Stomach

Group	Feeding period	Average IgY Ingested (mg)	Total IgY, mg/g of tissue
A	30 min	7.02	4.72 ± 1.21
B	1 hour	7.83	8.22 ± 1.62
C	2 hour	12.60	9.20 ± 1.42
D	4 hour	20.61	9.60 ± 1.34
E	24 hour	36.72	28.20 ± 3.25

Small Intestine

Group	Feeding period	Total IgY, mg/g of tissue
A	30 min	0.48 ± 0.08
B	1 hour	0.44 ± 0.11
C	2 hour	0.42 ± 0.10
D	4 hour	0.39 ± 0.07
E	24 hour	0.51 ± 0.06

[0051] As will be apparent to those skilled in the art, various modifications, adaptations and variations of the foregoing specific disclosure can be made without departing from the scope of the invention claimed herein. The various features and elements of the described invention may be

combined in a manner different from the combinations described or claimed herein, without departing from the scope of the invention.

## Claims

- [c1] 1. A composition for treating celiac disease or gluten sensitive enteropathy by oral administration to a person in need thereof, comprising anti-gluten egg yolk antibody.
- [c2] 2. The composition of claim 1 wherein the egg yolk antibody is a polyclonal antibody capable of binding gluten, wherein said gluten comprises one or more of gliadin, high molecular glutenin (HMG), and low molecular glutenin (LMG).
- [c3] 3. The composition of claim 2, wherein the polyclonal antibody comprises one or more specific antibodies prepared by: immunizing a fowl with one or more of gliadin, HMG, LMG, collecting eggs from the immunized fowl, separating the yolk of an antibody-containing egg from the white and preparing whole egg yolk powder or purified IgY from the eggs.
- [c4] 4. The composition of claim 3, wherein the specific antibody comprises an anti-gliadin antibody, an anti-HMG antibody, or an anti-LMG antibody.


- [c5] 5. The composition of claim 3, wherein the antibodies are capable of binding to a cocktail of proteins comprising a mixture of gliadin, HMG, and LMG in the substantially same proportion as found in wheat flour.
- [c6] 6. Use of egg yolk comprising anti-gluten antibodies in the preparation of a medicament or food product for the treatment or prevention of celiac disease.
- [c7] 7. Use of anti-gluten antibodies isolated from egg yolk in the preparation of a medicament or food product for the treatment or prevention of celiac disease.
- [c8] 8. A method of treating or preventing celiac disease comprising the step of administering a pharmaceutical or nutraceutical composition comprising egg yolk comprising anti-gluten antibodies to a person in need thereof.
- [c9] 9. A method of preventing gluten uptake in the digestive system comprising the steps of consuming a pharmaceutical or nutraceutical composition comprising anti-gluten avian antibodies.




# ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DIS- EASE

## Abstract

The present invention relates to compositions comprising egg yolk antibodies against gluten, including gliadin, high molecular glutenin, low molecular glutenin and mixtures of the three peptides. The antibodies may be produced by immunizing laying hens with immunogenic preparations of gluten and harvesting the eggs and yolks.



**FIGURE 1**



**FIGURE 2**